|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRKAB2 |
Gene summary for PRKAB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRKAB2 | Gene ID | 5565 |
| Gene name | protein kinase AMP-activated non-catalytic subunit beta 2 | |
| Gene Alias | PRKAB2 | |
| Cytomap | 1q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | O43741 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5565 | PRKAB2 | LZE4T | Human | Esophagus | ESCC | 3.84e-10 | 4.10e-01 | 0.0811 |
| 5565 | PRKAB2 | LZE24T | Human | Esophagus | ESCC | 2.52e-03 | 6.71e-02 | 0.0596 |
| 5565 | PRKAB2 | P2T-E | Human | Esophagus | ESCC | 6.40e-12 | 3.39e-01 | 0.1177 |
| 5565 | PRKAB2 | P4T-E | Human | Esophagus | ESCC | 4.60e-08 | 2.28e-01 | 0.1323 |
| 5565 | PRKAB2 | P5T-E | Human | Esophagus | ESCC | 2.49e-29 | 5.78e-01 | 0.1327 |
| 5565 | PRKAB2 | P8T-E | Human | Esophagus | ESCC | 1.02e-05 | 1.09e-01 | 0.0889 |
| 5565 | PRKAB2 | P9T-E | Human | Esophagus | ESCC | 1.93e-02 | 1.30e-01 | 0.1131 |
| 5565 | PRKAB2 | P10T-E | Human | Esophagus | ESCC | 2.99e-23 | 5.08e-01 | 0.116 |
| 5565 | PRKAB2 | P11T-E | Human | Esophagus | ESCC | 5.21e-13 | 4.39e-01 | 0.1426 |
| 5565 | PRKAB2 | P12T-E | Human | Esophagus | ESCC | 2.92e-17 | 2.46e-01 | 0.1122 |
| 5565 | PRKAB2 | P15T-E | Human | Esophagus | ESCC | 6.81e-20 | 4.18e-01 | 0.1149 |
| 5565 | PRKAB2 | P16T-E | Human | Esophagus | ESCC | 1.00e-09 | 1.23e-01 | 0.1153 |
| 5565 | PRKAB2 | P17T-E | Human | Esophagus | ESCC | 3.50e-04 | 2.75e-01 | 0.1278 |
| 5565 | PRKAB2 | P20T-E | Human | Esophagus | ESCC | 3.06e-11 | 3.08e-01 | 0.1124 |
| 5565 | PRKAB2 | P21T-E | Human | Esophagus | ESCC | 2.27e-14 | 3.51e-01 | 0.1617 |
| 5565 | PRKAB2 | P22T-E | Human | Esophagus | ESCC | 2.20e-07 | 2.33e-01 | 0.1236 |
| 5565 | PRKAB2 | P23T-E | Human | Esophagus | ESCC | 1.36e-09 | 2.91e-01 | 0.108 |
| 5565 | PRKAB2 | P24T-E | Human | Esophagus | ESCC | 2.63e-16 | 4.50e-01 | 0.1287 |
| 5565 | PRKAB2 | P26T-E | Human | Esophagus | ESCC | 2.66e-17 | 3.54e-01 | 0.1276 |
| 5565 | PRKAB2 | P27T-E | Human | Esophagus | ESCC | 6.56e-10 | 2.01e-01 | 0.1055 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:01201624 | Esophagus | ESCC | positive regulation of cold-induced thermogenesis | 57/8552 | 97/18723 | 6.43e-03 | 2.35e-02 | 57 |
| GO:01061066 | Esophagus | ESCC | cold-induced thermogenesis | 80/8552 | 144/18723 | 1.07e-02 | 3.65e-02 | 80 |
| GO:01201616 | Esophagus | ESCC | regulation of cold-induced thermogenesis | 80/8552 | 144/18723 | 1.07e-02 | 3.65e-02 | 80 |
| GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
| GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
| GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
| GO:00723303 | Liver | NAFLD | monocarboxylic acid biosynthetic process | 46/1882 | 214/18723 | 5.06e-07 | 3.07e-05 | 46 |
| GO:00066334 | Liver | NAFLD | fatty acid biosynthetic process | 29/1882 | 163/18723 | 1.67e-03 | 1.74e-02 | 29 |
| GO:19908452 | Liver | NAFLD | adaptive thermogenesis | 28/1882 | 157/18723 | 1.91e-03 | 1.93e-02 | 28 |
| GO:00016592 | Liver | NAFLD | temperature homeostasis | 29/1882 | 174/18723 | 4.48e-03 | 3.61e-02 | 29 |
| GO:01061063 | Liver | NAFLD | cold-induced thermogenesis | 25/1882 | 144/18723 | 4.66e-03 | 3.74e-02 | 25 |
| GO:01201613 | Liver | NAFLD | regulation of cold-induced thermogenesis | 25/1882 | 144/18723 | 4.66e-03 | 3.74e-02 | 25 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| GO:001605312 | Liver | Cirrhotic | organic acid biosynthetic process | 139/4634 | 316/18723 | 4.28e-14 | 3.83e-12 | 139 |
| GO:004639412 | Liver | Cirrhotic | carboxylic acid biosynthetic process | 137/4634 | 314/18723 | 1.40e-13 | 1.14e-11 | 137 |
| GO:007233011 | Liver | Cirrhotic | monocarboxylic acid biosynthetic process | 93/4634 | 214/18723 | 1.43e-09 | 6.16e-08 | 93 |
| GO:000663311 | Liver | Cirrhotic | fatty acid biosynthetic process | 70/4634 | 163/18723 | 2.57e-07 | 6.41e-06 | 70 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa040689 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
| hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
| hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
| hsa0421114 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
| hsa047105 | Esophagus | ESCC | Circadian rhythm | 24/4205 | 34/8465 | 1.09e-02 | 2.51e-02 | 1.29e-02 | 24 |
| hsa0492214 | Esophagus | ESCC | Glucagon signaling pathway | 64/4205 | 107/8465 | 2.18e-02 | 4.80e-02 | 2.46e-02 | 64 |
| hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa04714310 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa0406814 | Esophagus | ESCC | FoxO signaling pathway | 89/4205 | 131/8465 | 1.56e-05 | 7.98e-05 | 4.09e-05 | 89 |
| hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
| hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
| hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
| hsa0421115 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
| hsa0471012 | Esophagus | ESCC | Circadian rhythm | 24/4205 | 34/8465 | 1.09e-02 | 2.51e-02 | 1.29e-02 | 24 |
| hsa0492215 | Esophagus | ESCC | Glucagon signaling pathway | 64/4205 | 107/8465 | 2.18e-02 | 4.80e-02 | 2.46e-02 | 64 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRKAB2 | SNV | Missense_Mutation | c.403N>T | p.His135Tyr | p.H135Y | O43741 | protein_coding | tolerated(0.13) | benign(0.013) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| PRKAB2 | SNV | Missense_Mutation | rs782544337 | c.106A>G | p.Met36Val | p.M36V | O43741 | protein_coding | tolerated(0.1) | benign(0.02) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PRKAB2 | insertion | Frame_Shift_Ins | novel | c.94_95insGGACAATAGACATC | p.Glu32GlyfsTer44 | p.E32Gfs*44 | O43741 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PRKAB2 | SNV | Missense_Mutation | novel | c.109G>A | p.Val37Met | p.V37M | O43741 | protein_coding | tolerated(1) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PRKAB2 | SNV | Missense_Mutation | novel | c.93N>T | p.Lys31Asn | p.K31N | O43741 | protein_coding | tolerated(0.24) | benign(0.025) | TCGA-AA-3862-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PRKAB2 | SNV | Missense_Mutation | novel | c.381C>A | p.Phe127Leu | p.F127L | O43741 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| PRKAB2 | SNV | Missense_Mutation | c.671N>A | p.Ser224Tyr | p.S224Y | O43741 | protein_coding | deleterious(0.02) | possibly_damaging(0.733) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PRKAB2 | SNV | Missense_Mutation | c.754G>T | p.Val252Phe | p.V252F | O43741 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| PRKAB2 | SNV | Missense_Mutation | rs587727942 | c.245G>A | p.Arg82His | p.R82H | O43741 | protein_coding | deleterious(0) | benign(0.223) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PRKAB2 | SNV | Missense_Mutation | c.310C>T | p.Pro104Ser | p.P104S | O43741 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5565 | PRKAB2 | KINASE, ENZYME | SAPONARIN | SAPONARIN | 26471090 | |
| 5565 | PRKAB2 | KINASE, ENZYME | allosteric modulator | 252827478 | ||
| 5565 | PRKAB2 | KINASE, ENZYME | METFORMIN | METFORMIN | 26471090 | |
| 5565 | PRKAB2 | KINASE, ENZYME | metformin | METFORMIN | 22722338 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |